Organogenesis Holdings Inc. (ORGO) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

4/25

Growth 0 Margin 1 Expansion 3 Platform 0 Financial 0

latest quarter score

Earnings Reports

4
Organogenesis (ORGO) Q2 2026: Advanced Wound Care Volume Up 30% as Market Recalibrates Post-CMS Shock
August 07, 2026
6
Organogenesis (ORGO) Q1 2026: 58% Revenue Drop Forces $14M Cost Reset, Delays Recovery to Q4
May 08, 2026
10
OrganiGenesis (ORGO) Q4 2025: Advanced Wound Care Soars 83%, But CMS Policy Disruption Signals 2026 Revenue Drop
February 27, 2026
21
Organogenesis (ORGO) Q3 2025: Advanced Wound Care Surges 31% as CMS Policy Shift Unlocks Margin Tailwind
November 07, 2025
11
OrganoGenesis (ORGO) Q2 2025: Surgical and Sports Medicine Up 16% as CMS Payment Reform Reshapes Outlook
August 08, 2025
10
Organogenesis (ORGO) Q1 2025: Portfolio Optionality Counters 21% Revenue Drop Amid LCD Delay
July 05, 2025
Organogenesis Holdings (ORGO) Q4 2024: Advanced Wound Care Revenue Surges 27% Amid LCD Delays and Strategic Clinical Progress
February 27, 2025

Browse all companies